Ampio Pharmaceuticals, Inc. (AMPE.OB) Initiates Phase II Clinical Trial of Optina™ for Diabetic Macular Edema
Ampio Pharmaceuticals, Inc., a developer of innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease, recently announced that the company has initiated a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Vision loss, diabetic macular edema and diabetic retinopathy are complications of diabetes mellitus that occur in roughly one third of patients 10 years after the onset of diabetes. Optina™ is an oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina™ to significantly reduce diabetic macular edema…